Quick Answer
NewAmsterdam Pharma Co N.V. reported Cash and Equivalents of $490.00 million for fiscal year 2025.
NewAmsterdam Pharma Co N.V. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $490.00M | -36.5% |
| 2024 | $771.74M | +126.7% |
| 2023 | $340.45M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $538.41M | +27.4% | -4.5% |
| June 30, 2025 | $563.86M | — | -24.7% |
| March 31, 2025 | $748.42M | — | -3.0% |
| December 31, 2024 | $771.74M | — | +82.6% |
| September 30, 2024 | $422.73M | — | — |
- NewAmsterdam Pharma Co N.V. showed a decrease of -36.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, NewAmsterdam Pharma Co N.V.’s cash and equivalents has grown by 43.9% (from $340.45 million to $490.00 million).
- The most recent figure is from NewAmsterdam Pharma Co N.V.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: